Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality
monoclonal_antibody
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06398457CT.gov Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Transplant Rejection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Daratumumab (this asset) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early P1 | C · 39 |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Alemtuzumab | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Plerixafor | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | CCC |
+3 more in the Transplant Rejection cohort
Other indications for Daratumumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P4 | BB · 69 |
| Smoldering Plasma Cell Myeloma | — | P3 | BB · 65 |
| Diffuse Large B-Cell Lymphoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- BusulfanumMasonic Cancer Center, University of MinnesotaCCC
- CyclophosphamideMasonic Cancer Center, University of MinnesotaCCC
- SirolimusMasonic Cancer Center, University of MinnesotaCCC
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitMasonic Cancer Center, University of MinnesotaCCC
- FludarabineMasonic Cancer Center, University of MinnesotaCCC
Citation
Floatz Terminal. Daratumumab in Transplant Rejection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/daratumumab-transplant-rejection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →